English
Astrazeneca Pharma India Q2 Results
- BSE: 506820
- NSE: ASTRAZEN
- ISIN: INE203A01020
- Sector: Major Drugs
BSE
9,028.45
2.20 (0.02%)
2.20 (0.02%)Volume108.00
Updated: Wed 10 Dec, 2025 | 15:24:04
NSE
8,972.50
-61.00 (-0.68%)
-61.00 (-0.68%)Volume2.71 K
Updated: Wed 10 Dec, 2025 | 15:29:38
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
- Total Income₹559.09 Cr.(37.03%)
- Operating Profit₹67.32 Cr.(55.83%)
- Profit After Tax₹54.22 Cr.(41.09%)
- Operating Margin12.04%(13.72%)
Note: Comparison is on YoY basis
Quarterly - Astrazeneca Pharma India Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 25 | Jun 25 | QoQ Comp | Sep 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 491.77 | 462.13 | 6.41% | 364.80 | 34.81% |
| Depreciation/ Amortization | 2.57 | 16.57 | -84.49% | 9.32 | -72.42% |
| Operating Income | 67.32 | 64.18 | 4.89% | 43.20 | 55.83% |
| Net Income | 54.22 | 55.83 | -2.88% | 38.43 | 41.09% |
| Other Operating Expenses Total | 65.51 | 61.11 | 7.20% | 36.98 | 77.15% |
| Net Income Before Taxes | 72.82 | 74.70 | -2.52% | 51.03 | 42.70% |
| Total Revenue | 559.09 | 526.31 | 6.23% | 408.00 | 37.03% |
| Selling/ General/ Admin Expenses Total | 93.91 | 88.68 | 5.90% | 92.57 | 1.45% |
| Diluted Normalized EPS | 23.27 | 22.44 | 3.69% | 15.37 | 51.37% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.